Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01147627 |
|
Recruitment Status :
Completed
First Posted : June 22, 2010
Results First Posted : August 21, 2013
Last Update Posted : August 21, 2013
|
Sponsor:
Sun Yat-sen University
Collaborators:
Eli Lilly and Company
Amylin Pharmaceuticals, LLC.
Ministry of Health, China
Information provided by (Responsible Party):
Jianping Weng, Sun Yat-sen University
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to investigate and evaluate the effects of different interventions (1. exenatide, 2. insulin, 3. thiazolidinedione) on glycemic control and β-cell function in newly diagnosed drug-naïve type 2 diabetic patients.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Diabetes Mellitus, Type 2 Newly Diagnosed | Drug: exenatide injection Drug: Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R Drug: Pioglitazone | Not Applicable |
One of the fundamental defects in type 2 diabetes mellitus is declining β-cell function. Exenatide targets multiple metabolic disturbances in type 2 diabetes and exerts direct effects on β-cell, which indicates that it may not only contribute to the glucose control but also delay disease progression. There are trials demonstrated efficacy, safety and tolerability of exenatide. However, no study has compared the effects of exenatide with other hypoglycemic therapies with β cell protective function in newly diagnosed and drug-naïve type 2 diabetic patients. This current study is thus designed to evaluate the effects of exenatide, insulin and pioglitazone on glycemic control and β-cell function in newly diagnosed drug-naïve type 2 diabetic patients.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 416 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Comparison of Exenatide, Insulin or Pioglitazone on Glycaemic Control and β-cell Function in Drug-naïve Type 2 Diabetic Patients: A Multicentre Randomized Parallel-group Trial |
| Study Start Date : | August 2010 |
| Actual Primary Completion Date : | August 2012 |
| Actual Study Completion Date : | December 2012 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
| Active Comparator: Exenatide |
Drug: exenatide injection
Patients in exenatide group will be treated with exenatide (Byetta®, Eli Lilly and Company) 5 µg BID for the first 4 weeks and then 10 µg BID thereafter.
Other Name: Byetta®(Eli Lilly and Company) |
| Active Comparator: Premixed insulin analog |
Drug: Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R
Patients in insulin group will be treated with premixed insulin analog (Humalog Mix 25, Eli Lilly and Company). The initial insulin doses are 0.4 IU/kg per day(50% before breakfast and 50% before dinner). Insulin doses are titrated following a forced schedule according to blood glucose before breakfast and dinner.
Other Name: Humalog Mix 25®（Eli Lilly and Company) |
| Active Comparator: pioglitazone |
Drug: Pioglitazone
Patients in thiazolidinedione group will be treated with Pioglitazone 30mg daily as single dose. The dose will be increased to 45mg daily after 4 weeks. |
Primary Outcome Measures :
- the Comparison Between Treatment Groups of the Changes From Baseline in HbA1c at 48 Weeks [ Time Frame: 48 weeks ]
Secondary Outcome Measures :
- Percentage of Patients Achieving HbA1c <7% and ≤ 6.5% and Effect of Different Interventions on Fasting and Postprandial Plasma Glucose Concentration, Blood Pressure, Lipid Profiles [ Time Frame: 48 weeks ]
- β-cell Function (Acute Insulin Response During IVGTT; HOMA-B, Disposition Index and Proinsulin/Insulin Ratio) [ Time Frame: 48 weeks ]
- Safety and Tolerability in Different Groups [ Time Frame: 48 weeks ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 30 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- newly-diagnosed type 2 diabetic patients, drug naïve
- age 30~70 years
- HbA1c 7.0~10.0%
- BMI 20~35 kg/m2, stable body weight (≤10% variation) for at least 3 months prior to screening
- female patients of reproductive age should practice a reliable method of birth control throughout the study
Exclusion Criteria:
- acute or severe chronic diabetic complications
- congestive heart failure (NYHA grade Ⅲ~Ⅳ)
- severe gastrointestinal disease
- severe osteoporosis or history of pathological fracture,or use of bisphosphonates preparation
- other severe intercurrent illness
- serum aminotransferase (ALT and AST) level higher than 2 times of the upper normal limits and/or serum creatinie≥133µmol/L (1.5mg/dL)
- tested positive for glutamic acid decarboxylase antibody
- use of weight loss drugs, corticosteroids, drugs known to affect gastrointestinal motility, transplantation medications, or any investigational drug
- history of pancreatitis
- serum triglyceride ≥ 5.0 mmol/L
- pregnancy
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01147627
Locations
Show 25 study locations
Sponsors and Collaborators
Sun Yat-sen University
Eli Lilly and Company
Amylin Pharmaceuticals, LLC.
Ministry of Health, China
Investigators
| Study Director: | Jianping Weng, Doctor | Third Affiliated Hospital, Sun Yat-Sen University |
| Responsible Party: | Jianping Weng, professor, vice president, the third affiliated hospital of Sun Yat-sen University, Sun Yat-sen University |
| ClinicalTrials.gov Identifier: | NCT01147627 |
| Other Study ID Numbers: |
IIT-201007-WJP |
| First Posted: | June 22, 2010 Key Record Dates |
| Results First Posted: | August 21, 2013 |
| Last Update Posted: | August 21, 2013 |
| Last Verified: | June 2013 |
Keywords provided by Jianping Weng, Sun Yat-sen University:
|
diabetes mellitus, type 2 newly diagnosed exenatide premixed insulin analog |
thiazolidinedione β-cell function glycemic control |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Insulin Pioglitazone Exenatide Insulin Lispro Insulin, Globin Zinc |
Protamines Hypoglycemic Agents Physiological Effects of Drugs Anti-Obesity Agents Incretins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Heparin Antagonists Molecular Mechanisms of Pharmacological Action Coagulants |